Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 2/20 | 0.46 |
| ▸ | CKS1B | P61024 | 1/20 | 0.46 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.46 |
| ▸ | COMT | P21964 | 2/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | UBE2N | P61088 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29605109 | 1.00 | L3MBTL1 (0.58) | L3MBTL1CA1CA2PTGDR2HTR6 | |
| SCHEMBL1049380 | 0.87 | HTR6 (0.55) | L3MBTL1PTGDR2HTR6PKMCYP2C19 | |
| SCHEMBL16516197 | 0.87 | L3MBTL1 (0.55) | L3MBTL1CA1CA2PTGDR2HTR6 | |
| SCHEMBL1779514 | 0.86 | L3MBTL1 (0.60) | L3MBTL1PTGDR2HTR6COMTKDM4E | |
| SCHEMBL13302164 | 0.85 | L3MBTL1 (0.59) | L3MBTL1PTGDR2HTR6COMTELANE | |
| SCHEMBL12657360 | 0.84 | L3MBTL1 (0.58) | L3MBTL1PTGDR2HTR6COMTKDM4E | |
| SCHEMBL28523210 | 0.84 | L3MBTL1 (0.58) | L3MBTL1PTGDR2HTR6COMTKDM4E | |
| SCHEMBL9948819 | 0.83 | HTR6 (0.55) | L3MBTL1PTGDR2HTR6COMTKDM4E | |
| SCHEMBL28325459 | 0.83 | HTR6 (0.57) | L3MBTL1PTGDR2HTR6COMTKDM4E | |
| SCHEMBL257136 | 0.83 | KDM4E (0.64) | L3MBTL1CA2PTGDR2HTR6COMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115785134-A | Boric acid compound containing nitrogen heterocycle, preparation method and application | 浙大城市学院 | 2023-03-14 | — | — | CN | claimed |
| US-20150284388-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | VERTEX PHARMACEUTICALS INCORPORATED | 2015-10-08 | — | — | US | claimed |
| US-20150099884-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | VERTEX PHARMACEUTICALS INCORPORATED | 2015-04-09 | — | — | US | claimed |
| US-20140309421-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | VERTEX PHARMACEUTICALS INCORPORATED | 2014-10-16 | — | — | US | claimed |
| EP-2729465-A2 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | Vertex Pharmaceuticals Incorporated (US) | 2014-05-14 | — | — | EP | claimed |
| US-8513414-B2 | Processes and intermediates for producing azaindoles | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-20 | — | — | US | claimed |
| US-20130102782-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-25 | — | — | US | claimed |
| WO-2013006634-A9 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-21 | — | — | WO | claimed |
| WO-2013006634-A2 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-10 | — | — | WO | claimed |
| EP-4720058-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | Casma Therapeutics, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024249291-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | CASMA THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| EP-4447954-A1 | HETEROCYCLIC COMPOUNDS AS 5HT2A BIASED AGONISTS | Icahn School of Medicine at Mount Sinai (US) | 2024-10-23 | — | — | EP | disclosed |
| US-RE49851-E1 | Pyridinylaminopyrimidine derivatives, preparation process and use thereof | SHANGHAI ALLIST PHARMACEUTICALS CO., LTD. (CN) | 2024-02-27 | — | — | US | disclosed |
| CN-117430589-A | 2-aminopyrimidine compound or salt thereof, and preparation method and application thereof | 励缔(杭州)医药科技有限公司 | 2024-01-23 | — | — | CN | disclosed |
| US-7507826-B2 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-03-24 | — | — | US | disclosed |
| US-20070043063-A1 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2007-02-22 | — | — | US | disclosed |
| US-20070043063-A1 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2007-02-22 | — | — | US | disclosed |
| US-20070043063-A1 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2007-02-22 | — | — | US | disclosed |
| EP-1730146-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005095400-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099884-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | JAK2, JAK3, JAK1 | L3MBTL1 4344/4885CA1 3890/4885CA2 3879/4885 |
| US-20140309421-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | JAK2, JAK3, JAK1 | L3MBTL1 4344/4885CA1 3890/4885CA2 3879/4885 |
| US-20070043063-A1 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | LCK, PDXK, CHUK | L3MBTL1 2920/4885CA1 2903/4885CA2 1107/4885 |
| US-20130102782-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | JAK2, JAK3, JAK1 | L3MBTL1 4344/4885CA1 3890/4885CA2 3879/4885 |
| US-20150284388-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | JAK2, JAK3, JAK1 | L3MBTL1 4344/4885CA1 3890/4885CA2 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.